Company Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts.
Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Jan 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Craig C. Parker M.B.A. |
Contact Details
Address: 171 Oyster Point Boulevard South San Francisco, California United States | |
| Website | https://www.surrozen.com |
Stock Details
| Ticker Symbol | SRZN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001824893 |
| CUSIP Number | 86889P109 |
| ISIN Number | US86889P2083 |
| Employer ID | 98-1556622 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig C. Parker M.B.A. | Chief Executive Officer, President & Director |
| Charles Williams | Chief Financial Officer, Chief Operating Officer & Corporate Secretary |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Li Yang Ph.D. | Executive Vice President of Research |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Esther Jhun | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Nov 01, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 02, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |